{"ticker": {"uuid": "5cce6a56-c9cf-41bc-90a0-d4805a73391f", "symbol": "TVTX", "name": "Travere Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZVVBSVZKY3pieHE0QnljWTRFa1ViYXJsTFhxWkhTc0ZpRFo0cWN4QmpYQTdBcXdLclpUSFlON1ZRb3NVLURheUV5eGtWNFdZbGNKeVVYYzZsWXhaei1Lbnl5RC1OZnk2dUZ3VldHMmJ3Y3I5OHdNMUJoU1JtcVlqLTlHMTJSZTRUNUY1TmYzMUhGeVFkb0d6Y1NGUkZvZzJvMlBnUzJVbkdDTndyWlhLQXZHek1uV1RyQ0p3Y1dNLXdseUV5RUZUR2Q2d2ZFTHRjVDJuTEtrSGM?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T06:59:21+00:00", "published_display": "17 Jul 2026 06:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Travere Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Travere Therapeutics, Inc. breached their fiduciary duties through potential self-dealing. This probe could lead to damages and corporate governance reforms that would benefit shareholders. Long-term investors are", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-travere-therapeutics-hubungi-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:39:32", "published_display": "17 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026", "summary": "Travere Therapeutics announced inducement equity grants to six new employees on July 10, 2026, totaling 41,600 shares of common stock. These grants, comprising stock options and restricted stock units (RSUs), were made outside the 2018 Equity Incentive Plan as inducements for new", "url": "https://www.biospace.com/press-releases/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-july-10-2026", "source_name": "BioSpace", "published_at": "2026-07-13T23:47:49", "published_display": "13 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTRX6388605 Bond Risk Profile", "summary": "This page provides a risk profile for the RTRX6388605 bond issued by Travere Therapeutics, Inc. The bond has a 0.5% coupon rate and matures on May 15, 2032. It details general bond information, including credit risk assessment and the ability to access analyst ratings.", "url": "https://www.tradingview.com/symbols/FINRA-RTRX6388605/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-13T17:40:29", "published_display": "13 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RTRX6388605 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for RTRX6388605, a bond issued by Travere Therapeutics, Inc. Key metrics include an issue date of May 11, 2026, maturity date of May 15, 2032, and a coupon rate of 0.50%. The bond has an outstanding amount of $525 million USD and a face value ", "url": "https://www.tradingview.com/symbols/FINRA-RTRX6388605/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T13:11:42", "published_display": "13 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Travere Therapeutics, Inc. (Nasdaq: TVTX) announced inducement equity grants totaling 41,600 shares to six new employees on July 10, 2026. These grants, comprising stock options and restricted stock units (RSUs), were made as inducements for employment in accordance with Nasdaq L", "url": "https://www.lincolnjournal.com/online_features/press_releases/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_9c93af1b-6456-537d-9b7a-aeb5bc5abdf8.html", "source_name": "lincolnjournal.com", "published_at": "2026-07-10T23:47:49", "published_display": "10 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Travere hires receive 41,600-share stock and RSU package", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbGlYdnN2NWVTR0ozSjVweTF6VzJraW12Vk5Gb3VPZHEwX2hvYUxldHhZNXV6MUFhLWdtY0IyMGF3U21nYVdRRDJSekVTQmVZYkxxZjUycWpONXctT0thUGtfOU9abHo2LTl3anVsWDRRd01tbXJHNzBqZTFRWHpQUGpuWkdzcU1TRGpDcGh1RUZ0SmlpUUMyT2JVY3AzY3hPalQyTXdCQ2xSQ2MzZl93aHlNWHNMd051MXhhenFtMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T21:00:00+00:00", "published_display": "10 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027", "summary": "Travere Therapeutics' accounting chief, Sandra Calvin, is set to retire in 2027. The article provides details regarding this upcoming leadership change.", "url": "https://www.moomoo.com/news/post/72777057/travere-therapeutics-accounting-chief-sandra-calvin-to-retire-in-2027", "source_name": "Moomoo", "published_at": "2026-07-10T13:11:21", "published_display": "10 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor", "summary": "Travere Therapeutics announced that Sandra Calvin will retire as Chief Accounting Officer (CAO) and Principal Accounting Officer. John Torell, the current Vice President, Controller, is expected to succeed her to ensure a smooth transition. Torell is anticipated to serve as CAO a", "url": "https://www.tradingview.com/news/tradingview:15b2d7cbf28cf:0-sandra-calvin-to-retire-as-travere-therapeutics-cao-john-torell-named-successor/", "source_name": "TradingView", "published_at": "2026-07-09T21:12:53", "published_display": "09 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires", "summary": "Travere Therapeutics (NASDAQ: TVTX) announced that its chief accounting officer (CAO) and principal accounting officer (PAO), Sandra Calvin, plans to retire in February 2027 after the company files its Annual Report on Form 10-K. John Torell, the current Vice President, Controlle", "url": "https://www.stocktitan.net/sec-filings/TVTX/8-k-travere-therapeutics-inc-reports-material-event-796ac5e42940.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:10:53", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib", "summary": "Everest Medicines announced the closing of its exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class oral BTK inhibitor. Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligibl", "url": "https://macaubusiness.com/everest-medicines-announces-close-of-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib/", "source_name": "Macau Business", "published_at": "2026-07-08T09:09:48", "published_display": "08 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Travere\u2019s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative?", "summary": "Travere Therapeutics (TVTX) was recently removed from several Russell value and small-cap indices in late June 2026. This action could lead to forced portfolio rebalancing by index-tracking funds and reshape the company's investment narrative and risk profile, despite its core gr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/will-traveres-removal-from-key-russell-value-indices-change", "source_name": "Simply Wall Street", "published_at": "2026-07-07T14:41:09", "published_display": "07 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (TVTX) Could Be 3% Undervalued As Russell Value Exits Stir Questions", "summary": "Travere Therapeutics (TVTX) has been removed from several Russell value indices, prompting questions about its valuation. Despite this, the company has shown strong share price performance, with a 79.73% return over 90 days and a 289.73% return over one year. Simply Wall St indic", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-could-be-3-undervalued-as-russell/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T13:11:23", "published_display": "06 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVWNKSWxsbEd1SmRmV2JhVVM1SjVtWjg3dWdvdU5GWGlOdkdXYm01X2pFRGlrM3BFdk9Mc0lxOGtnV0J4aGN6bkFGc2VUeDA1bFV0WTAtM0NwMDV1TElWT0REaWI5Y2ttbnRYbC15MmxmYl8wVkg1Vk9FN3JKakdQRjk1aEF1anJVMDdvelNKS0hrRG00V0d5U0NFdXkwSWE4bmJiMmNLTEJLN2pHNHBfX3A5RQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI\u00ae (sparsentan) in IgA Nephropathy", "summary": "Travere Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to methods of using FILSPARI\u00ae (sparsentan) in IgA nephropathy. This patent is expected to provide U.S. coverage until October 2037 and will b", "url": "https://www.natlawreview.com/press-releases/travere-therapeutics-receives-notice-allowance-us-patent-and-trademark", "source_name": "The National Law Review", "published_at": "2026-06-30T16:09:03", "published_display": "30 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Travere Therapeutics (TVTX) Rebalancing Its Risk Profile With New Capital Tools And R&D Leadership Changes?", "summary": "Travere Therapeutics recently experienced removal from Russell value and small-cap indices, filed a significant shelf registration for common stock, and announced upcoming changes in its R&D leadership. These developments prompt questions about how institutional ownership, fundin", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/is-travere-therapeutics-tvtx-rebalancing-its-risk-profile-wi", "source_name": "Simply Wall Street", "published_at": "2026-06-30T00:39:55", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark", "summary": "Travere Therapeutics, Inc. (NasdaqGM: TVTX) has been removed from the Russell 2000 Value Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including favorable analyst assessments of its drug Filspari and executive changes. The company remai", "url": "https://www.marketscreener.com/news/travere-therapeutics-inc-nasdaqgm-tvtx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f722", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:12:52", "published_display": "29 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (TVTX)", "summary": "This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) with an \"Overweight Bias\" due to strong sentiment across all time horizons. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details three AI-generate", "url": "https://news.stocktradersdaily.com/news_release/23/Understanding_Momentum_Shifts_in_TVTX_062926101202_1782742322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T10:12:52", "published_display": "29 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "This article provides financial information for Travere Therapeutics, Inc. (NASDAQ: TVTX), specifically focusing on its forward price-to-earnings ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating the period, value, and change fo", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:12:52", "published_display": "28 Jun 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article provides the enterprise value to revenue forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It lists \"Period,\" \"Value,\" \"Change,\" and \"Change %\" as key metrics related to this financial ratio. The information is presented within a TradingView interface, indicating", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:41:13", "published_display": "28 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article focuses on the enterprise value to EBITDA forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The content itself seems to be a title with navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:40:38", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article discusses the enterprise value to EBIT forward for Travere Therapeutics, Inc. (NASDAQ: TVTX), a company in the Pharmaceuticals: Major sector. It appears to list financial data or an analysis of this metric, accessible on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:09:48", "published_display": "27 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX)", "summary": "This article provides an overview of Travere Therapeutics, Inc. (NASDAQ: TVTX) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial performance, such as earnings per share and revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:41:20", "published_display": "26 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TVTX Maintained by Guggenheim -- Price Target Raised to $65", "summary": "Guggenheim analyst Vamil Divan maintained a 'Buy' rating for Travere Therapeutics (TVTX) and raised the price target to $65.00, reflecting confidence in the company's pipeline and future performance. Despite the positive analyst outlook, GuruFocus indicates that TVTX is significa", "url": "https://www.gurufocus.com/news/8931905/tvtx-maintained-by-guggenheim-price-target-raised-to-65", "source_name": "GuruFocus", "published_at": "2026-06-25T15:15:35", "published_display": "25 Jun 2026 15:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TVTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, analyst forecasts, and recent financial performance. Analysts predict a price range of $43.00 to $70.00 for TVTX, with a consensus price target of $57.71. The company has sh", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:35", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics stock hits 52-week high at 56.9 USD", "summary": "Travere Therapeutics (TVTX) stock reached a new 52-week high of $56.90, reflecting a 267% total return over the past year and a market capitalization of $5.26 billion. InvestingPro analysis suggests the stock is undervalued, and recent developments include positive Phase 3 study ", "url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-569-usd-93CH-4758411", "source_name": "Investing.com", "published_at": "2026-06-24T15:19:01", "published_display": "24 Jun 2026 15:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Travere Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 4 for Travere Therapeutics Inc. on June 22. It is a brief public notice about the regulatory filing, indicating an insider transaction or change in ownership, without providing details within the snippet. Viewers are in", "url": "https://ng.investing.com/news/stock-market-news/form-4-travere-therapeutics-inc-for-22-june-93CH-2568743", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:48:00", "published_display": "22 Jun 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4", "summary": "Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported a bona fide gift of 468 shares of common stock to a donor-advised fund. This charitable transfer occurred on June 22, 2026, and was reported at $0.00 per share, indicating a non-market transaction. Following this g", "url": "https://www.stocktitan.net/sec-filings/TVTX/form-4-travere-therapeutics-inc-insider-trading-activity-d3434595c31f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:13", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-shows-favorable-setup-151450482.html", "source_name": "MT Newswires", "published_at": "2026-06-22T15:14:50+00:00", "published_display": "22 Jun 2026 15:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Travere Therapeutics to $61 From $55, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-travere-110035369.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:00:35+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Travere Therapeutics Inc (TVTX), noting its current valuation score is 9.85, ranking 11th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -246.62 and mentions that relevant data for P/B, P/S,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:36", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an in-depth look into the shareholder structure of Travere Therapeutics Inc (TVTX), detailing its major shareholders and institutional holdings. It lists key investment firms and their respective proportions, along with a historical overview of institutional", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvtx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:34", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Chief Research Officer William Rote to Retire", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-chief-research-officer-205710288.html", "source_name": "MT Newswires", "published_at": "2026-06-16T20:57:10+00:00", "published_display": "16 Jun 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-announces-planned-retirement-203000079.html", "source_name": "Business Wire", "published_at": "2026-06-16T20:30:00+00:00", "published_display": "16 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOakwxREpTSC1uVVlVSHYtdnZJR01ERGdsNWtCX1E3dEd0UFVNV1VIUWdaYTZGTzU1Q1pOaUpncElEbTFSUGRoQnoxWjJMZy1WQ0UtWEJmWXFqVjFGTmZmVXVTWXZUekF2LTVjZ0o1dldXV1c4Q1hMQkVfcW9kMHNHVC0ya1pFdnRyZVN4djVuOTNzeEVnVmJxbTJfbU84QlNI?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/travere-therapeutics-presents-long-term-140900075.html", "source_name": "Business Wire", "published_at": "2026-06-04T14:09:00+00:00", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere receives patent allowance for Filspari IgA nephropathy use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSmZKcFpZLWpWRW5ldGxMWDVyZHJTanBEUk5NTlppZXVtbXN5UlVhOERwV2JYaU9ITGl2ZFBNSnd5RTJfcHRwQkkxelFYUk5fcFVQajl5Q3dlcXRUbDUwV2g2Q0YyOEJseHp5akJiYVF4MlBMS0lycXJEQXNFZ0xzQ2ZEN2JTU084dFJ5cWR0Q0hFOUktaUdpbEkxMldUUzZQaVJOR00tNUFILXpBOXpCd0NVekdvcS02Zm1zRWpIblQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "8,000 Travere (TVTX) shares sold as director exercises options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUnpJN2VCelVjcUxjaGhlZjJyS0JVdEVTdXVDT04zcEp0WXF4R013SGdRTGZGWXZuNnpZcXl0WVNIcUtqYUo3X3EwazhhaEp1b0dBd3pxMFIwd3NCeXJoQnRRVE9oSFJybTFzd0QyV0xpMmk0NlN4U3hCNnoxSmZRNUFRT0FaMnNNbkxZZ1U5M3ZPb3ZqbnROVVUwTU5vR3gzNlZ0czVQRzVUMDZtckRkRUZFTThCY0drX3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive Moat", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNWW5kYnhnU05EYzF3V2s0MDBscmduNTVVSjBWcUxiTnV0bWUxVk40d3BKS1JOZlhORTJNS1FOLWpWbk9MVFNYdjg2MjktNFB1MjVOUVBhMElNdmlEaG5jV21IdkJ5dXdxd0xuMUc2VmVZdlpHNXdVQW5VdjI3NkpqWFBCdzNoczFSNEZ5VVdVUzh4THdJb2JaYUpXbVNUUXpIMlM2c1pDZw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQaHozdUNGT3B4UHd3bTRybHpDOWllUmlUZ3JqVThJemdFZWpqOU8yT2FxZzN2alFQWUNVZlBBZVNVcG5pTFhlUnFNRHVaWGhvUWVQM1FNNG9jVW1BcS1XWlp6Vm1sZ3IxS1p2Unh6T0laQ0gtUGJNNVk3Z0dha091SlRjVjFWRUQ1TWEzV1RNaTFMNGg5V1diOWdRNUlKSjNJaGQ1ODkzMA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Travere (TVTX) is an Overlooked Growth Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPaVRuRWVLajkwUGE4cndhdGkzZ2ZWOGxEV2RJMWpHS010V3RUdVBHMzNIVThfdl94OVZyb0I5SU1EUmpaUU1lWF9JRUNfQ2FqS1RpRkFUbmg0WE0zbTUtbEZCckxlYjVCTmk0QlpUa2syQ2JsS1NZZmp4bm5fNUU0MzhkWWllUWd5VE9WaV9LSmlPczZFTWU4TVFoYWhWNzhZ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) director sells 8K shares after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbTRxcjJ5STZCV25uRWFQblE5eGp1Q2RPTjdOdUlqdVpiLU1BY2E3amdVUWR2TmpzcEdYYUx1UVA3Q2Rnd2VTWnN0ZXJ3a0pieG04SEdKdHpnZnFYUDNUUVRQbUtLVUxaU2gwd3FZWXRfdnpnRkZGR2FESFVmdG1IMXkzSXFKM0ZHaE1JbXFQM3Rtc1RmQTNVUFMwR3NlanhQNjh2SkJ5X19JUERKSDVTMXdOeW9ZVFRIb3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxONzJOY0hzQ0QyMDFZcFpBSmk1NmVWcmg3NUNqNGdkWl9lZXRDcHM4X3FDNHlzbW9FM2w5OGt4OW0tUTJfSDRlVTBQZkVXZko4cXJ5X0NZbzV2dTdPbld5bE1DWDJrYVlFdlRxNXZNREFESkpuRjM3Q0tPNnl6WUJiTTY1dEtYYmxyNmZ4MkZyLVVWZw?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (TVTX) legal chief sells 51,500 shares after option exercises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOd3RyNUVRdy01TEJpZldpallLSmtqQ09VUDlKM2FIVXlYZWc3X2gxOHp6NFRKUEU0YXhlejAxcHI1cDhIS1VGMjY2VXlKX3RVRF9IV2J5QUJEdDg4bzhBWkY0aGF5dzlkOFpKMWs1S2l6eHhXOGpXVjFIWmpmUFJRU3RZQjA3dHRFcUgzR2lZX2Y0VHUxeFJja1RhRUZRdGNvS0tlbklqTUVIXy14YXU3cG92ZkJyMGtuZXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Travere Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQblBFaVdjUFdjZzEtcnB3NHBHS0g2aEVKQTJuSzFpZWRpQV8xcWpJWkpNM1MxSkpRUjNOSmFMbkRnajE1YlFuTjJTZHZ4cVBxM01LMnpqTEI2NWxKMG1wODlSaWx1cmpib2ExN3ExRFNnVzM1aGJfYTd4cE1hX1Zwa0ZNT29OUjBGSW1FWjBJUkVfWldVSDllS2Q2dy1hbWRCVzNj?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "37,500-share planned sale at TVTX (NASDAQ: TVTX) \u2014 insider notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcGl5NWxLQlludHhyT3NHRjMxR1I1ak1yc1pZVWVwbHpjUnY0cWRoWm5qMkh0dkdPTVFQRzJVbnE2SG9MRGlkdXFwUlE1c1FuMUtmNm94RWFJUnhBQmNhMEtVLVJRaXU2REJfU3p4R2NWMVRXSk5SVExOYVJiWkdBNnFEaVZmX01aTDRjckRFaEowTm1HRFZWSC1WeEtRRU9hUHhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdi1SU1RSa3FHVHRMcktPbE1FaGhpRGdvRjZfSEt4UmNEUmZjeTVUSzd2ZWZxS3Yyd1VNU0pEOVFwVGZVbE12NFE5UXJ2NGxPeHRPZE9NRl9QLVE0VVd2aWpoQ2wxSzVQdVdaMjFkc0tMeTlMYU5zWE1EWnBDMEQycTYtb2J4U3NZVnZNR05fNmRrNEFuQ3lqZU9ObGxKOTYtY1JDZTZPd1Y4dmJ0dkxuaGdYRG9rMk4yOFFZSU1vNDdFM0JBWTQyX1VfOHlWSWdDbmFmbWZVMnhHTFE?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-14T00:37:57+00:00", "published_display": "14 Apr 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (NASDAQ: TVTX) director exercises options, sells 10,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNYnZueDdaclhFYXhrdXB4ZWVHQU5leU9mQTJRbjhSSUtCOEVPSWNqWVdSUHB4bERxal9aOVhpV01XZ2YyTTd5ZVR4Vm92d0t5QTRIalRKQ0xuX0Q1dWhFSTV6RTBQWHpZNFFObWpKWllLaXZGNlJDM0NrVEtETk5GOTMyT3FpYkw3OVZHMkhGWjM5bFd5My1EeW9BSkdzUmJrVVZCSzZGX2lXTGQyMmJiaXY1MW5lVm1TLUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere therapeutics CEO Dube sells $1.8m in TVTX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOU14dUs1X0s3c29KQ3ZVRlJOWVlCb3J6SURlWnpOMHE3S29pb0Ftb1BMaXhVX1NUT3c2Q25OTzFsTWNUSUtnbUc1Z2p6bTVzVkEzV0I5eWltQXU4TlgzTkczODhvNmVoS2JvSk51ZmdpWmtCLTRyY3ZPQzY5UWhnUFAwdUhxa3RUT1FpVmc2R2pMZUIyNWN4Z192WFZvdFJ4VVdGY2xncWNlczBfX2tneEdaOW5hdm1JNHc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZVVBSVZKY3pieHE0QnljWTRFa1ViYXJsTFhxWkhTc0ZpRFo0cWN4QmpYQTdBcXdLclpUSFlON1ZRb3NVLURheUV5eGtWNFdZbGNKeVVYYzZsWXhaei1Lbnl5RC1OZnk2dUZ3VldHMmJ3Y3I5OHdNMUJoU1JtcVlqLTlHMTJSZTRUNUY1TmYzMUhGeVFkb0d6Y1NGUkZvZzJvMlBnUzJVbkdDTndyWlhLQXZHek1uV1RyQ0p3Y1dNLXdseUV5RUZUR2Q2d2ZFTHRjVDJuTEtrSGM?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T06:59:21+00:00", "published_display": "17 Jul 2026 06:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law firm probes Travere Therapeutics officers for possible self-dealing harming shareholders", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Travere Therapeutics, Inc. breached their fiduciary duties through potential self-dealing. This probe could lead to damages and corporate governance reforms that would benefit shareholders. Long-term investors are", "url": "https://pluang.com/en/news-feed/kuehn-law-ajakan-pemegang-saham-travere-therapeutics-hubungi-firma-hukum", "source_name": "Pluang", "published_at": "2026-07-17T01:39:32", "published_display": "17 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026", "summary": "Travere Therapeutics announced inducement equity grants to six new employees on July 10, 2026, totaling 41,600 shares of common stock. These grants, comprising stock options and restricted stock units (RSUs), were made outside the 2018 Equity Incentive Plan as inducements for new", "url": "https://www.biospace.com/press-releases/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-july-10-2026", "source_name": "BioSpace", "published_at": "2026-07-13T23:47:49", "published_display": "13 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTRX6388605 Bond Risk Profile", "summary": "This page provides a risk profile for the RTRX6388605 bond issued by Travere Therapeutics, Inc. The bond has a 0.5% coupon rate and matures on May 15, 2032. It details general bond information, including credit risk assessment and the ability to access analyst ratings.", "url": "https://www.tradingview.com/symbols/FINRA-RTRX6388605/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-13T17:40:29", "published_display": "13 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTRX6388605 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for RTRX6388605, a bond issued by Travere Therapeutics, Inc. Key metrics include an issue date of May 11, 2026, maturity date of May 15, 2032, and a coupon rate of 0.50%. The bond has an outstanding amount of $525 million USD and a face value ", "url": "https://www.tradingview.com/symbols/FINRA-RTRX6388605/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T13:11:42", "published_display": "13 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Travere Therapeutics, Inc. (Nasdaq: TVTX) announced inducement equity grants totaling 41,600 shares to six new employees on July 10, 2026. These grants, comprising stock options and restricted stock units (RSUs), were made as inducements for employment in accordance with Nasdaq L", "url": "https://www.lincolnjournal.com/online_features/press_releases/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_9c93af1b-6456-537d-9b7a-aeb5bc5abdf8.html", "source_name": "lincolnjournal.com", "published_at": "2026-07-10T23:47:49", "published_display": "10 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Travere hires receive 41,600-share stock and RSU package", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbGlYdnN2NWVTR0ozSjVweTF6VzJraW12Vk5Gb3VPZHEwX2hvYUxldHhZNXV6MUFhLWdtY0IyMGF3U21nYVdRRDJSekVTQmVZYkxxZjUycWpONXctT0thUGtfOU9abHo2LTl3anVsWDRRd01tbXJHNzBqZTFRWHpQUGpuWkdzcU1TRGpDcGh1RUZ0SmlpUUMyT2JVY3AzY3hPalQyTXdCQ2xSQ2MzZl93aHlNWHNMd051MXhhenFtMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T21:00:00+00:00", "published_display": "10 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027", "summary": "Travere Therapeutics' accounting chief, Sandra Calvin, is set to retire in 2027. The article provides details regarding this upcoming leadership change.", "url": "https://www.moomoo.com/news/post/72777057/travere-therapeutics-accounting-chief-sandra-calvin-to-retire-in-2027", "source_name": "Moomoo", "published_at": "2026-07-10T13:11:21", "published_display": "10 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor", "summary": "Travere Therapeutics announced that Sandra Calvin will retire as Chief Accounting Officer (CAO) and Principal Accounting Officer. John Torell, the current Vice President, Controller, is expected to succeed her to ensure a smooth transition. Torell is anticipated to serve as CAO a", "url": "https://www.tradingview.com/news/tradingview:15b2d7cbf28cf:0-sandra-calvin-to-retire-as-travere-therapeutics-cao-john-torell-named-successor/", "source_name": "TradingView", "published_at": "2026-07-09T21:12:53", "published_display": "09 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires", "summary": "Travere Therapeutics (NASDAQ: TVTX) announced that its chief accounting officer (CAO) and principal accounting officer (PAO), Sandra Calvin, plans to retire in February 2027 after the company files its Annual Report on Form 10-K. John Torell, the current Vice President, Controlle", "url": "https://www.stocktitan.net/sec-filings/TVTX/8-k-travere-therapeutics-inc-reports-material-event-796ac5e42940.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:10:53", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib", "summary": "Everest Medicines announced the closing of its exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class oral BTK inhibitor. Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligibl", "url": "https://macaubusiness.com/everest-medicines-announces-close-of-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib/", "source_name": "Macau Business", "published_at": "2026-07-08T09:09:48", "published_display": "08 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Travere\u2019s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative?", "summary": "Travere Therapeutics (TVTX) was recently removed from several Russell value and small-cap indices in late June 2026. This action could lead to forced portfolio rebalancing by index-tracking funds and reshape the company's investment narrative and risk profile, despite its core gr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/will-traveres-removal-from-key-russell-value-indices-change", "source_name": "Simply Wall Street", "published_at": "2026-07-07T14:41:09", "published_display": "07 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (TVTX) Could Be 3% Undervalued As Russell Value Exits Stir Questions", "summary": "Travere Therapeutics (TVTX) has been removed from several Russell value indices, prompting questions about its valuation. Despite this, the company has shown strong share price performance, with a 79.73% return over 90 days and a 289.73% return over one year. Simply Wall St indic", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-could-be-3-undervalued-as-russell/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T13:11:23", "published_display": "06 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVWNKSWxsbEd1SmRmV2JhVVM1SjVtWjg3dWdvdU5GWGlOdkdXYm01X2pFRGlrM3BFdk9Mc0lxOGtnV0J4aGN6bkFGc2VUeDA1bFV0WTAtM0NwMDV1TElWT0REaWI5Y2ttbnRYbC15MmxmYl8wVkg1Vk9FN3JKakdQRjk1aEF1anJVMDdvelNKS0hrRG00V0d5U0NFdXkwSWE4bmJiMmNLTEJLN2pHNHBfX3A5RQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI\u00ae (sparsentan) in IgA Nephropathy", "summary": "Travere Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to methods of using FILSPARI\u00ae (sparsentan) in IgA nephropathy. This patent is expected to provide U.S. coverage until October 2037 and will b", "url": "https://www.natlawreview.com/press-releases/travere-therapeutics-receives-notice-allowance-us-patent-and-trademark", "source_name": "The National Law Review", "published_at": "2026-06-30T16:09:03", "published_display": "30 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Travere Therapeutics (TVTX) Rebalancing Its Risk Profile With New Capital Tools And R&D Leadership Changes?", "summary": "Travere Therapeutics recently experienced removal from Russell value and small-cap indices, filed a significant shelf registration for common stock, and announced upcoming changes in its R&D leadership. These developments prompt questions about how institutional ownership, fundin", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/is-travere-therapeutics-tvtx-rebalancing-its-risk-profile-wi", "source_name": "Simply Wall Street", "published_at": "2026-06-30T00:39:55", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark", "summary": "Travere Therapeutics, Inc. (NasdaqGM: TVTX) has been removed from the Russell 2000 Value Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including favorable analyst assessments of its drug Filspari and executive changes. The company remai", "url": "https://www.marketscreener.com/news/travere-therapeutics-inc-nasdaqgm-tvtx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f722", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:12:52", "published_display": "29 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (TVTX)", "summary": "This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) with an \"Overweight Bias\" due to strong sentiment across all time horizons. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details three AI-generate", "url": "https://news.stocktradersdaily.com/news_release/23/Understanding_Momentum_Shifts_in_TVTX_062926101202_1782742322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T10:12:52", "published_display": "29 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "This article provides financial information for Travere Therapeutics, Inc. (NASDAQ: TVTX), specifically focusing on its forward price-to-earnings ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating the period, value, and change fo", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:12:52", "published_display": "28 Jun 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article provides the enterprise value to revenue forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It lists \"Period,\" \"Value,\" \"Change,\" and \"Change %\" as key metrics related to this financial ratio. The information is presented within a TradingView interface, indicating", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:41:13", "published_display": "28 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article focuses on the enterprise value to EBITDA forward for Travere Therapeutics, Inc. (NASDAQ: TVTX). It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The content itself seems to be a title with navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:40:38", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Travere Therapeutics, Inc. \u2013 NASDAQ:TVTX", "summary": "The article discusses the enterprise value to EBIT forward for Travere Therapeutics, Inc. (NASDAQ: TVTX), a company in the Pharmaceuticals: Major sector. It appears to list financial data or an analysis of this metric, accessible on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:09:48", "published_display": "27 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX)", "summary": "This article provides an overview of Travere Therapeutics, Inc. (NASDAQ: TVTX) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial performance, such as earnings per share and revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:41:20", "published_display": "26 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TVTX Maintained by Guggenheim -- Price Target Raised to $65", "summary": "Guggenheim analyst Vamil Divan maintained a 'Buy' rating for Travere Therapeutics (TVTX) and raised the price target to $65.00, reflecting confidence in the company's pipeline and future performance. Despite the positive analyst outlook, GuruFocus indicates that TVTX is significa", "url": "https://www.gurufocus.com/news/8931905/tvtx-maintained-by-guggenheim-price-target-raised-to-65", "source_name": "GuruFocus", "published_at": "2026-06-25T15:15:35", "published_display": "25 Jun 2026 15:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TVTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, analyst forecasts, and recent financial performance. Analysts predict a price range of $43.00 to $70.00 for TVTX, with a consensus price target of $57.71. The company has sh", "url": "https://www.tradingview.com/symbols/NASDAQ-TVTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:35", "published_display": "25 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics stock hits 52-week high at 56.9 USD", "summary": "Travere Therapeutics (TVTX) stock reached a new 52-week high of $56.90, reflecting a 267% total return over the past year and a market capitalization of $5.26 billion. InvestingPro analysis suggests the stock is undervalued, and recent developments include positive Phase 3 study ", "url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-569-usd-93CH-4758411", "source_name": "Investing.com", "published_at": "2026-06-24T15:19:01", "published_display": "24 Jun 2026 15:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Travere Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 4 for Travere Therapeutics Inc. on June 22. It is a brief public notice about the regulatory filing, indicating an insider transaction or change in ownership, without providing details within the snippet. Viewers are in", "url": "https://ng.investing.com/news/stock-market-news/form-4-travere-therapeutics-inc-for-22-june-93CH-2568743", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:48:00", "published_display": "22 Jun 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4", "summary": "Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported a bona fide gift of 468 shares of common stock to a donor-advised fund. This charitable transfer occurred on June 22, 2026, and was reported at $0.00 per share, indicating a non-market transaction. Following this g", "url": "https://www.stocktitan.net/sec-filings/TVTX/form-4-travere-therapeutics-inc-insider-trading-activity-d3434595c31f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:13", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-shows-favorable-setup-151450482.html", "source_name": "MT Newswires", "published_at": "2026-06-22T15:14:50+00:00", "published_display": "22 Jun 2026 15:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Travere Therapeutics to $61 From $55, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-travere-110035369.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:00:35+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Travere Therapeutics Inc (TVTX), noting its current valuation score is 9.85, ranking 11th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -246.62 and mentions that relevant data for P/B, P/S,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:36", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an in-depth look into the shareholder structure of Travere Therapeutics Inc (TVTX), detailing its major shareholders and institutional holdings. It lists key investment firms and their respective proportions, along with a historical overview of institutional", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvtx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:34", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Chief Research Officer William Rote to Retire", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-chief-research-officer-205710288.html", "source_name": "MT Newswires", "published_at": "2026-06-16T20:57:10+00:00", "published_display": "16 Jun 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-announces-planned-retirement-203000079.html", "source_name": "Business Wire", "published_at": "2026-06-16T20:30:00+00:00", "published_display": "16 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOakwxREpTSC1uVVlVSHYtdnZJR01ERGdsNWtCX1E3dEd0UFVNV1VIUWdaYTZGTzU1Q1pOaUpncElEbTFSUGRoQnoxWjJMZy1WQ0UtWEJmWXFqVjFGTmZmVXVTWXZUekF2LTVjZ0o1dldXV1c4Q1hMQkVfcW9kMHNHVC0ya1pFdnRyZVN4djVuOTNzeEVnVmJxbTJfbU84QlNI?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/travere-therapeutics-presents-long-term-140900075.html", "source_name": "Business Wire", "published_at": "2026-06-04T14:09:00+00:00", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere receives patent allowance for Filspari IgA nephropathy use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSmZKcFpZLWpWRW5ldGxMWDVyZHJTanBEUk5NTlppZXVtbXN5UlVhOERwV2JYaU9ITGl2ZFBNSnd5RTJfcHRwQkkxelFYUk5fcFVQajl5Q3dlcXRUbDUwV2g2Q0YyOEJseHp5akJiYVF4MlBMS0lycXJEQXNFZ0xzQ2ZEN2JTU084dFJ5cWR0Q0hFOUktaUdpbEkxMldUUzZQaVJOR00tNUFILXpBOXpCd0NVekdvcS02Zm1zRWpIblQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8,000 Travere (TVTX) shares sold as director exercises options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUnpJN2VCelVjcUxjaGhlZjJyS0JVdEVTdXVDT04zcEp0WXF4R013SGdRTGZGWXZuNnpZcXl0WVNIcUtqYUo3X3EwazhhaEp1b0dBd3pxMFIwd3NCeXJoQnRRVE9oSFJybTFzd0QyV0xpMmk0NlN4U3hCNnoxSmZRNUFRT0FaMnNNbkxZZ1U5M3ZPb3ZqbnROVVUwTU5vR3gzNlZ0czVQRzVUMDZtckRkRUZFTThCY0drX3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive Moat", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNWW5kYnhnU05EYzF3V2s0MDBscmduNTVVSjBWcUxiTnV0bWUxVk40d3BKS1JOZlhORTJNS1FOLWpWbk9MVFNYdjg2MjktNFB1MjVOUVBhMElNdmlEaG5jV21IdkJ5dXdxd0xuMUc2VmVZdlpHNXdVQW5VdjI3NkpqWFBCdzNoczFSNEZ5VVdVUzh4THdJb2JaYUpXbVNUUXpIMlM2c1pDZw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQaHozdUNGT3B4UHd3bTRybHpDOWllUmlUZ3JqVThJemdFZWpqOU8yT2FxZzN2alFQWUNVZlBBZVNVcG5pTFhlUnFNRHVaWGhvUWVQM1FNNG9jVW1BcS1XWlp6Vm1sZ3IxS1p2Unh6T0laQ0gtUGJNNVk3Z0dha091SlRjVjFWRUQ1TWEzV1RNaTFMNGg5V1diOWdRNUlKSjNJaGQ1ODkzMA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Travere (TVTX) is an Overlooked Growth Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPaVRuRWVLajkwUGE4cndhdGkzZ2ZWOGxEV2RJMWpHS010V3RUdVBHMzNIVThfdl94OVZyb0I5SU1EUmpaUU1lWF9JRUNfQ2FqS1RpRkFUbmg0WE0zbTUtbEZCckxlYjVCTmk0QlpUa2syQ2JsS1NZZmp4bm5fNUU0MzhkWWllUWd5VE9WaV9LSmlPczZFTWU4TVFoYWhWNzhZ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics (NASDAQ: TVTX) director sells 8K shares after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbTRxcjJ5STZCV25uRWFQblE5eGp1Q2RPTjdOdUlqdVpiLU1BY2E3amdVUWR2TmpzcEdYYUx1UVA3Q2Rnd2VTWnN0ZXJ3a0pieG04SEdKdHpnZnFYUDNUUVRQbUtLVUxaU2gwd3FZWXRfdnpnRkZGR2FESFVmdG1IMXkzSXFKM0ZHaE1JbXFQM3Rtc1RmQTNVUFMwR3NlanhQNjh2SkJ5X19JUERKSDVTMXdOeW9ZVFRIb3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxONzJOY0hzQ0QyMDFZcFpBSmk1NmVWcmg3NUNqNGdkWl9lZXRDcHM4X3FDNHlzbW9FM2w5OGt4OW0tUTJfSDRlVTBQZkVXZko4cXJ5X0NZbzV2dTdPbld5bE1DWDJrYVlFdlRxNXZNREFESkpuRjM3Q0tPNnl6WUJiTTY1dEtYYmxyNmZ4MkZyLVVWZw?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (TVTX) legal chief sells 51,500 shares after option exercises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOd3RyNUVRdy01TEJpZldpallLSmtqQ09VUDlKM2FIVXlYZWc3X2gxOHp6NFRKUEU0YXhlejAxcHI1cDhIS1VGMjY2VXlKX3RVRF9IV2J5QUJEdDg4bzhBWkY0aGF5dzlkOFpKMWs1S2l6eHhXOGpXVjFIWmpmUFJRU3RZQjA3dHRFcUgzR2lZX2Y0VHUxeFJja1RhRUZRdGNvS0tlbklqTUVIXy14YXU3cG92ZkJyMGtuZXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Travere Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQblBFaVdjUFdjZzEtcnB3NHBHS0g2aEVKQTJuSzFpZWRpQV8xcWpJWkpNM1MxSkpRUjNOSmFMbkRnajE1YlFuTjJTZHZ4cVBxM01LMnpqTEI2NWxKMG1wODlSaWx1cmpib2ExN3ExRFNnVzM1aGJfYTd4cE1hX1Zwa0ZNT29OUjBGSW1FWjBJUkVfWldVSDllS2Q2dy1hbWRCVzNj?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "37,500-share planned sale at TVTX (NASDAQ: TVTX) \u2014 insider notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcGl5NWxLQlludHhyT3NHRjMxR1I1ak1yc1pZVWVwbHpjUnY0cWRoWm5qMkh0dkdPTVFQRzJVbnE2SG9MRGlkdXFwUlE1c1FuMUtmNm94RWFJUnhBQmNhMEtVLVJRaXU2REJfU3p4R2NWMVRXSk5SVExOYVJiWkdBNnFEaVZmX01aTDRjckRFaEowTm1HRFZWSC1WeEtRRU9hUHhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdi1SU1RSa3FHVHRMcktPbE1FaGhpRGdvRjZfSEt4UmNEUmZjeTVUSzd2ZWZxS3Yyd1VNU0pEOVFwVGZVbE12NFE5UXJ2NGxPeHRPZE9NRl9QLVE0VVd2aWpoQ2wxSzVQdVdaMjFkc0tMeTlMYU5zWE1EWnBDMEQycTYtb2J4U3NZVnZNR05fNmRrNEFuQ3lqZU9ObGxKOTYtY1JDZTZPd1Y4dmJ0dkxuaGdYRG9rMk4yOFFZSU1vNDdFM0JBWTQyX1VfOHlWSWdDbmFmbWZVMnhHTFE?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-14T00:37:57+00:00", "published_display": "14 Apr 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere (NASDAQ: TVTX) director exercises options, sells 10,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNYnZueDdaclhFYXhrdXB4ZWVHQU5leU9mQTJRbjhSSUtCOEVPSWNqWVdSUHB4bERxal9aOVhpV01XZ2YyTTd5ZVR4Vm92d0t5QTRIalRKQ0xuX0Q1dWhFSTV6RTBQWHpZNFFObWpKWllLaXZGNlJDM0NrVEtETk5GOTMyT3FpYkw3OVZHMkhGWjM5bFd5My1EeW9BSkdzUmJrVVZCSzZGX2lXTGQyMmJiaXY1MW5lVm1TLUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Travere therapeutics CEO Dube sells $1.8m in TVTX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOU14dUs1X0s3c29KQ3ZVRlJOWVlCb3J6SURlWnpOMHE3S29pb0Ftb1BMaXhVX1NUT3c2Q25OTzFsTWNUSUtnbUc1Z2p6bTVzVkEzV0I5eWltQXU4TlgzTkczODhvNmVoS2JvSk51ZmdpWmtCLTRyY3ZPQzY5UWhnUFAwdUhxa3RUT1FpVmc2R2pMZUIyNWN4Z192WFZvdFJ4VVdGY2xncWNlczBfX2tneEdaOW5hdm1JNHc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 63, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 42, "score": 53, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 23.45, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 56.59, "latest_week": "2026-07-10", "one_week_move": -0.6, "four_week_move": 8.7, "twelve_week_move": 38.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.296389, "market_dynamics_buy_signal": false, "relative_strength": 50.689406, "fair_value_gap": 192.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.8575, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +8.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.6% over one week, +8.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today"}], "updated_at": "2026-07-17T16:48:50.374669+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}